Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

Authors: Sonia Molina-Pinelo, Amancio Carnero, Fernando Rivera, Purificacion Estevez-Garcia, Juan Manuel Bozada, Maria Luisa Limon, Marta Benavent, Javier Gomez, Maria Dolores Pastor, Manuel Chaves, Rocio Suarez, Luis Paz-Ares, Fernando de la Portilla, Andres Carranza-Carranza, Isabel Sevilla, Luis Vicioso, Rocio Garcia-Carbonero

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

MicroRNAs (miRNAs) are involved in numerous biological and pathological processes including colorectal cancer (CRC). The aim of our study was to evaluate the ability of miRNA expression patterns to predict chemotherapy response in a cohort of 78 patients with metastatic CRC (mCRC).

Methods

We examined expression levels of 667 miRNAs in the training cohort and evaluated their potential association with relevant clinical endpoints. We identified a miRNA profile that was analysed by RT-qPCR in an independent cohort. For a set of selected miRNAs, bioinformatic target predictions and pathway analysis were also performed.

Results

Eight miRNAs (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) were significant predictors of response to chemotherapy in the training cohort. In addition, overexpression of miR-107, miR-337-5p and miR-99a-3p, and underexpression of miR-889, were also significantly associated with improved progression-free and/or overall survival. MicroRNA-107 and miR-99a-3p were further validated in an independent cohort as predictive markers for chemotherapy response. In addition, an inverse correlation was confirmed in our study population between miR-107 levels and mRNA expression of several potential target genes (CCND1, DICER1, DROSHA and NFKB1).

Conclusions

MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
3.
Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009, 27 (19): 3109-3116. 10.1200/JCO.2008.20.6771.CrossRefPubMed
4.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18 (16): 2938-2947.PubMed
5.
Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, Tabah-Fisch I, Cassidy J: Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol. 2009, 20 (2): 244-250.CrossRefPubMed
6.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355 (9209): 1041-1047. 10.1016/S0140-6736(00)02034-1.CrossRefPubMed
7.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343 (13): 905-914. 10.1056/NEJM200009283431302.CrossRefPubMed
8.
Garcia-Carbonero R, Gomez Espana MA, Casado Saenz E, Alonso Orduna V, Cervantes Ruiperez A, Gallego Plazas J, Garcia Alfonso P, Juez Martel I, Gonzalez Flores E, Lomas Garrido M, Isla Casado D: SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol. 2010, 12 (11): 729-734. 10.1007/s12094-010-0587-4.CrossRefPubMed
9.
Aranda E, Abad A, Carrato A, Cervantes A, Garcia-Foncillas J, Garcia Alfonso P, Garcia Carbonero R, Gomez Espana A, Tabernero JM, Diaz-Rubio E: Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol. 2011, 13 (3): 162-178. 10.1007/s12094-011-0636-7.CrossRefPubMed
10.
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006, 314 (5797): 268-274. 10.1126/science.1133427.CrossRefPubMed
11.
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al: The genomic landscapes of human breast and colorectal cancers. Science. 2007, 318 (5853): 1108-1113. 10.1126/science.1145720.CrossRefPubMed
12.
Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68 (14): 5795-5802. 10.1158/0008-5472.CAN-08-0951.CrossRefPubMed
13.
Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M: High Let-7a MicroRNA levels in KRAS-mutated colorectal carcinomas May rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist. 2012, 17 (6): 823-829. 10.1634/theoncologist.2012-0081.CrossRefPubMedPubMedCentral
14.
Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C, Purrello M: Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther. 2010, 9 (12): 3396-3409. 10.1158/1535-7163.MCT-10-0137.CrossRefPubMed
15.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 2005, 120 (5): 635-647. 10.1016/j.cell.2005.01.014.CrossRefPubMed
16.
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009, 28 (10): 1385-1392. 10.1038/onc.2008.474.CrossRefPubMed
17.
Tsang WP, Kwok TT: The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009, 30 (6): 953-959. 10.1093/carcin/bgp094.CrossRefPubMed
18.
Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008, 47 (11): 939-946. 10.1002/gcc.20596.CrossRefPubMedPubMedCentral
19.
Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9 (6): 582-589. 10.1038/embor.2008.74.CrossRefPubMedPubMedCentral
20.
Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Puré E, Agami R: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008, 10 (2): 202-210. 10.1038/ncb1681.CrossRefPubMed
21.
Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009, 8: 102-10.1186/1476-4598-8-102.CrossRefPubMedPubMedCentral
22.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007, 72 (5–6): 397-402.PubMed
23.
Molina-Pinelo S, Suarez R, Pastor MD, Nogal A, Marquez-Martin E, Martin-Juan J, Carnero A, Paz-Ares L: Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers. 2012, 32 (4): 221-230. 10.1155/2012/873749.CrossRefPubMedPubMedCentral
24.
Dweep H, Sticht C, Pandey P, Gretz N: miRWalk–database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011, 44 (5): 839-847. 10.1016/j.jbi.2011.05.002.CrossRefPubMed
25.
Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, Pan Q: microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene. 2011, 31 (36): 4045-4053.CrossRefPubMedPubMedCentral
26.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral
27.
Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ: Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer. 2010, 103 (4): 532-541. 10.1038/sj.bjc.6605787.CrossRefPubMedPubMedCentral
28.
Pan Q, Bao LW, Teknos TN, Merajver SD: Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 2006, 66 (19): 9379-9384. 10.1158/0008-5472.CAN-06-2646.CrossRefPubMedPubMedCentral
29.
Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ: P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A. 2010, 107 (14): 6334-6339. 10.1073/pnas.0911082107.CrossRefPubMedPubMedCentral
30.
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998, 394 (6692): 485-490. 10.1038/28867.CrossRefPubMed
31.
Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL: Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001, 158 (4): 1325-1334. 10.1016/S0002-9440(10)64083-7.CrossRefPubMedPubMedCentral
32.
Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W, Zhang A: Upregulation of MicroRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett. 2014, 588 (4): 538-544. 10.1016/j.febslet.2013.12.009.CrossRefPubMed
33.
Chen RH, Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, Shyy JY, Liang JT, Chen RH: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012, 72 (14): 3631-3641. 10.1158/0008-5472.CAN-12-0667.CrossRefPubMed
34.
Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012, 18 (8): 2316-2325. 10.1158/1078-0432.CCR-11-2381.CrossRefPubMed
35.
Leong S, Messersmith WA, Tan AC, Eckhardt SG: Novel agents in the treatment of metastatic colorectal cancer. Cancer J. 2010, 16 (3): 273-282. 10.1097/PPO.0b013e3181e076c5.CrossRefPubMed
36.
Carnero A: Novel inhibitors of the PI3K family. Expert Opin Investig Drugs. 2009, 18 (9): 1265-1277. 10.1517/13543780903066798.CrossRefPubMed
37.
Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des. 2010, 16 (1): 34-44. 10.2174/138161210789941865.CrossRefPubMed
38.
Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. 10.1038/nrc839.CrossRefPubMed
39.
Paz-Ares L, Blanco-Aparicio C, Garcia-Carbonero R, Carnero A: Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol. 2009, 11 (9): 572-579. 10.1007/s12094-009-0407-x.CrossRefPubMed
Metadata
Title
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
Authors
Sonia Molina-Pinelo
Amancio Carnero
Fernando Rivera
Purificacion Estevez-Garcia
Juan Manuel Bozada
Maria Luisa Limon
Marta Benavent
Javier Gomez
Maria Dolores Pastor
Manuel Chaves
Rocio Suarez
Luis Paz-Ares
Fernando de la Portilla
Andres Carranza-Carranza
Isabel Sevilla
Luis Vicioso
Rocio Garcia-Carbonero
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-656

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma

Research article

Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis

Research article

Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer

Research article

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

Research article

BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study

Research article

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits